Leerink Partners Raises Price Target on Diplomat Pharmacy (DPLO) to $36 Following 1Q Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil hovers near $100 on rising Middle East tensions
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
After-Hours Stock Movers 05/09: (STMP) (OPK) (HALO) Higher; (NLNK) (GPS) (BLOX) (RAX) Lower (more...)
May 9, 2016 6:25 PM EDTNewLink Genetics Corporation (NASDAQ: NLNK) 34.5% LOWER; announced today results of its Phase 3 clinical trial for algenpantucel-L for patients with resected pancreatic cancer. The IMPRESS Phase 3 study of algenpantucel-L for patients with resected pancreatic cancer did not achieve its primary endpoint. Overall survival from time of randomization was 29.3 months for both groups combined. There was no statistically significant difference between the two groups. The median survival was 30.4 months and 27.3 months for the control and study groups, respectively. There was also no statistical difference for long-term survival. Three year survival was... More
Diplomat Pharmacy (DPLO) Tops Q1 EPS by 5c
May 9, 2016 4:15 PM EDTDiplomat Pharmacy (NYSE: DPLO) reported Q1 EPS of $0.23, $0.05 better than the analyst estimate of $0.18. Revenue for the quarter came in at $995.9 million versus the consensus estimate of $982.87 million.
For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.
... MoreTrading Radar for 5/9: Tyson Foods (TSN), Stratasys (SSYS), Wayfair (W), MBIA (MBI) Report
May 6, 2016 2:45 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Earnings:
AES Corp (Nasdaq: AES) - consensus EPS $0.20
Alaska Communications Systems (Nasdaq: ALSK) - consensus EPS $0.00
Altisource Residential (Nasdaq: RESI) - consensus loss $0.06
Apricus Biosciences (Nasdaq: APRI) - consensus loss $0.09
Armstrong World (Nasdaq: AWI) - consensus EPS $0.41
BIND Therapeutics (Nasdaq: BIND) - consensus loss... More
